Aileron Therapeutics, Inc. (ALRN)

Aileron Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	60	14	11	51	42	16
Market Cap Growth	434.68%	28.63%	-78.89%	20.49%	165.52%	28.63%
Enterprise Value	48	-3	-10	5	28	3
PE Ratio	-	-0.88	-0.39	-1.95	-2.00	-0.54
PB Ratio	0.65	0.14	0.58	1.16	3.48	0.99
P/FCF Ratio	-1.48	-0.70	-0.43	-2.14	-2.09	-0.60
P/OCF Ratio	-1.47	-0.70	-0.43	-2.15	-2.07	-0.60
EV/EBITDA Ratio	-1.01	0.22	0.39	-0.20	-1.35	-0.09
EV/EBIT Ratio	-1.00	0.22	0.38	-0.20	-1.34	-0.09
EV/FCF Ratio	-0.89	0.17	0.42	-0.22	-1.40	-0.10
Debt / Equity Ratio	-	0.00	0.00	0.00	0.03	0.31
Debt / EBITDA Ratio	-	0.00	0.00	-0.01	-0.02	-0.17
Debt / FCF Ratio	-	0.00	0.00	-0.01	-0.02	-0.19
Quick Ratio	2.66	3.95	6.28	10.19	3.64	3.13
Current Ratio	2.82	4.17	6.46	10.69	4.12	3.35
Return on Equity (ROE)	-33.80%	-46.10%	-103.10%	-49.50%	-165.80%	-143.80%
Return on Assets (ROA)	-31.10%	-42.00%	-88.70%	-45.80%	-99.50%	-95.50%
Return on Capital (ROIC)	-20.22%	-16.55%	-148.19%	-60.38%	-163.33%	-142.11%
Earnings Yield	-30.32%	-113.64%	-253.93%	-51.32%	-50.00%	-184.30%
FCF Yield	-34.20%	-142.77%	-231.03%	-46.77%	-47.91%	-167.08%
Buyback Yield / Dilution	-82.81%	-1.31%	-2.23%	-154.70%	-42.11%	-66.48%
Total Shareholder Return	-82.81%	-1.31%	-2.23%	-154.70%	-42.11%	-66.48%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).